| Cash Flow | 2025-07-31 |
|---|---|
| Change in fair value of warrant liabilities | 243,000 |
| Change in fair value of derivative liability | 0 |
| Change in fair value of warrant asset femasys | -1,215,000 |
| Change in fair value of investment tnf | -2,839,000 |
| Change in fair value of warrants - tnf | -4,832,000 |
| Unrealized loss on marketable equity securities | -104,463 |
| Net income (loss) | -8,360,096 |
| Gain on related party investment tnf | 0 |
| Adjustment from accrued liabilities to warrant liabilities | 469,000 |
| Gain on re-fair value of warrants | 106,000 |
| Stock-based compensation | 60,492 |
| Change in fair value of convertible note receivable - femasys | 912,000 |
| (increase) decrease in prepaid expenses and other current assets | 14,421 |
| Increase in accounts payable | 66,005 |
| Decrease in accrued expenses | -1,006,424 |
| Net cash and cash equivalents used in operating activities | -1,993,981 |
| Investment in preferred stock and warrants | 0 |
| Net cash and cash equivalents used in investing activities | 0 |
| Repurchase of common stock, net | 0 |
| Redemption of preferred stock | 0 |
| Net cash and cash equivalents used in financing activities | 0 |
| Effect of currency rate exchange on cash and cash equivalents | 123 |
| Net decrease in cash and cash equivalents | -1,993,858 |
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)